Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 3/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4424310 | 0.89 | FGFR2 (0.38) | CNR2FGFR2FGFR4FGFR3RAB9A | |
| SCHEMBL4428560 | 0.86 | NPSR1 (0.38) | CES2CES1NPC1RAB9AMEN1 | |
| SCHEMBL1683712 | 0.83 | GAA (0.46) | MEN1KMT2AALDH1A1SMN1; SMN2CDK5 | |
| SCHEMBL4422771 | 0.80 | TUBB1 (0.40) | — | |
| SCHEMBL1683709 | 0.80 | CNR2 (0.48) | CNR2FGFR2KDRFGFR4FGFR3 | |
| SCHEMBL724015 | 0.79 | CNR2 (0.55) | CNR2FGFR2KDRFGFR4FGFR3 | |
| SCHEMBL4420802 | 0.78 | CNR2 (0.45) | CNR2PARP1NPC1RAB9AHTT | |
| SCHEMBL1683750 | 0.73 | MAPK14 (0.33) | CES2CES1PARP1NPC1ALDH1A1 | |
| SCHEMBL4418724 | 0.70 | ALDH1A1 (0.37) | MEN1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL724565 | 0.69 | MAPT (0.44) | CNR2FGFR2FGFR3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865196-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-15 | — | — | US | disclosed |
| US-10301285-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2019-03-28 | — | — | US | disclosed |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2018-04-05 | — | — | US | disclosed |
| EP-3289876-A1 | COMPOUNDS FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2959900-A1 | COMPOUND FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9029408-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8592465-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2303021-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010074776-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | HCCS, NQO1, CCNY | CNR2 495/4885FGFR2 852/4885KDR 2872/4885 |
| US-10865196-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | CNR2 3924/4885FGFR2 346/4885KDR 4147/4885 |
| US-10301285-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | CNR2 3924/4885FGFR2 346/4885KDR 4147/4885 |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | CNR2 3924/4885FGFR2 346/4885KDR 4147/4885 |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | CNR2 3924/4885FGFR2 346/4885KDR 4147/4885 |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | CNR2 3924/4885FGFR2 346/4885KDR 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.